Segui questo link per vedere altri tipi di pubblicazioni sul tema: Daunorubicin.

Articoli di riviste sul tema "Daunorubicin"

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "Daunorubicin".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.

1

Drevin, Guillaume, Marie Briet, Caroline Bazzoli, et al. "Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial." Pharmaceutics 14, no. 4 (2022): 792. http://dx.doi.org/10.3390/pharmaceutics14040792.

Testo completo
Abstract (sommario):
Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia. The aim of the study is to assess the joint daunorubicin/daunorubicinol PK profile and to define an optimal population PK study design. Fourteen patients were enrolled in the PK ancillary study of the BIG-1 trial and 6–8 samples were taken up to 24 h after administration of the first dose of daunorubicin (90 mg/m2/day). Daunorubicin and daunorubicinol quantifications were assessed using a validated liq
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Zucchetti, Massimo, Amerigo Boiardi, Antonio Silvani, Idria Parisi, Stefano Piccolrovazzi, and Maurizio D'Incalci. "Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin." Cancer Chemotherapy and Pharmacology 44, no. 2 (1999): 173–76. http://dx.doi.org/10.1007/s002800050964.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
3

&NA;. "Daunorubicin see Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 354 (1991): 8. http://dx.doi.org/10.2165/00128415-199103540-00027.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Choi, Min-Koo, Im-Sook Song, Dae-Duk Kim, Suk-Jae Chung, and Chang-Koo Shim. "Altered Pharmacokinetics of Daunorubicin in Rats with CCl4-Induced Hepatic Injury." Journal of Pharmacy & Pharmaceutical Sciences 10, no. 4 (2007): 443. http://dx.doi.org/10.18433/j3mw28.

Testo completo
Abstract (sommario):
PURPOSE. The effect of CCl4-induced experimental hepatic injury (CCl4-EHI) on the pharmacokinetics of daunorubicin was investigated systemically in rats, in an attempt to elucidate the major determinants of the effect of CCl4-EHI on the pharmacokinetics of the drug. METHODS. CCl4-EHI was induced in rats by a single intraperitoneal injection of CCl4 (1mL/kg rat), and a 24 h fasting period. Daunorubicin was administered intravenously to control and EHI rats at a dose of 11.3 mg/mL/kg and the in vivo pharmacokinetics was studied. The in vitro uptake of the drug into isolated hepatocytes and canal
Gli stili APA, Harvard, Vancouver, ISO e altri
5

Cusack, B. J., Stephan P. Young, Robert E. Vestal, and Richard D. Olson. "Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat." Cancer Chemotherapy and Pharmacology 39, no. 6 (1997): 505–12. http://dx.doi.org/10.1007/s002800050606.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Nikanjam, Mina, Edmund Capparelli, Jeffrey E. Lancet, Jonathan E. Kolitz, Arthur C. Louie, and Gary J. Schiller. "Enhanced Cytarabine and Daunorubicin Population Pharmacokinetics When Administered As CPX-351: A Novel Liposomal Formulation Not Requiring Dose Reduction for Mild Renal or Hepatic Dysfunction." Blood 128, no. 22 (2016): 3955. http://dx.doi.org/10.1182/blood.v128.22.3955.3955.

Testo completo
Abstract (sommario):
Abstract Introduction: CPX-351 (Vyxeos) is a novel liposomal formulation of cytarabine and daunorubicin in a fixed 5:1 molar ratio that has been studied in a phase III clinical trial for secondary acute myeloid leukemia. The current study investigated pharmacokinetic and pharmacodynamic relationships of this liposomal formulation. Methods: CPX-351 pharmacokinetic data from a Phase I study of patients (median age: 62, range 24-81 years) with relapsed and refractory acute myeloid leukemia were used for the analysis. CPX-351 was given as a 90-minute infusion on days 1, 3, and 5 of induction thera
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Alves, Ana Catarina, Daniela Ribeiro, Miguel Horta, José L. F. C. Lima, Cláudia Nunes, and Salette Reis. "A biophysical approach to daunorubicin interaction with model membranes: relevance for the drug's biological activity." Journal of The Royal Society Interface 14, no. 133 (2017): 20170408. http://dx.doi.org/10.1098/rsif.2017.0408.

Testo completo
Abstract (sommario):
Daunorubicin is extensively used in chemotherapy for diverse types of cancer. Over the years, evidence has suggested that the mechanisms by which daunorubicin causes cytotoxic effects are also associated with interactions at the membrane level. The aim of the present work was to study the interplay between daunorubicin and mimetic membrane models composed of different ratios of 1,2-dimyristoyl- sn -glycero- 3 -phosphocholine (DMPC), sphingomyelin (SM) and cholesterol (Chol). Several biophysical parameters were assessed using liposomes as mimetic model membranes. Thereby, the ability of daunoru
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Albrecht, K. W., S. Leenstra, P. J. M. Bakker, et al. "High concentration of daunorubicin and daunorubicinol in human malignant astrocytomas after systemic administration of liposomal daunorubicin." Clinical Neurology and Neurosurgery 99 (July 1997): S231. http://dx.doi.org/10.1016/s0303-8467(97)82346-3.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
9

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1184 (2008): 15. http://dx.doi.org/10.2165/00128415-200811840-00044.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
10

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 562 (1995): 6. http://dx.doi.org/10.2165/00128415-199505620-00017.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
11

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 392 (1992): 5. http://dx.doi.org/10.2165/00128415-199203920-00013.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
12

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 398 (1992): 6. http://dx.doi.org/10.2165/00128415-199203980-00014.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
13

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 407 (1992): 5. http://dx.doi.org/10.2165/00128415-199204070-00010.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
14

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 898 (2002): 6. http://dx.doi.org/10.2165/00128415-200208980-00016.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
15

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1263 (2009): 15. http://dx.doi.org/10.2165/00128415-200912630-00046.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
16

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1243 (2009): 18–19. http://dx.doi.org/10.2165/00128415-200912430-00055.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
17

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1257 (2009): 17–18. http://dx.doi.org/10.2165/00128415-200912570-00053.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
18

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 338 (1991): 4. http://dx.doi.org/10.2165/00128415-199103380-00018.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
19

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 357 (1991): 6. http://dx.doi.org/10.2165/00128415-199103570-00024.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
20

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1297 (2010): 21. http://dx.doi.org/10.2165/00128415-201012970-00062.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
21

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1333 (2011): 19. http://dx.doi.org/10.2165/00128415-201113330-00057.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
22

Hempel, Georg, Petra Schulze-Westhoff, Silke Flege, and Joachim Boos. "Quantification of daunorubicin and daunorubicinol in plasma by capillary electrophoresis." Journal of Chromatography B: Biomedical Sciences and Applications 758, no. 2 (2001): 221–28. http://dx.doi.org/10.1016/s0378-4347(01)00185-2.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
23

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1395 (2012): 17–18. http://dx.doi.org/10.2165/00128415-201213950-00056.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
24

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1397 (2012): 14. http://dx.doi.org/10.2165/00128415-201213970-00046.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
25

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 751 (1999): 7. http://dx.doi.org/10.2165/00128415-199907510-00019.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
26

&NA;. "Daunorubicin/mitoxantrone." Reactions Weekly &NA;, no. 1158 (2007): 12. http://dx.doi.org/10.2165/00128415-200711580-00029.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
27

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1363 (2011): 16. http://dx.doi.org/10.2165/00128415-201113630-00058.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
28

&NA;. "Daunorubicin/pirarubicin." Reactions Weekly &NA;, no. 1366 (2011): 13. http://dx.doi.org/10.2165/00128415-201113660-00044.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
29

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1371 (2011): 14. http://dx.doi.org/10.2165/00128415-201113710-00049.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
30

&NA;. "Doxorubicin/daunorubicin." Reactions Weekly &NA;, no. 439 (1993): 8. http://dx.doi.org/10.2165/00128415-199304390-00040.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
31

&NA;. "Doxorubicin/daunorubicin." Reactions Weekly &NA;, no. 471 (1993): 8. http://dx.doi.org/10.2165/00128415-199304710-00036.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
32

&NA;. "Daunorubicin liposomal." Reactions Weekly &NA;, no. 814 (2000): 6–7. http://dx.doi.org/10.2165/00128415-200008140-00011.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
33

&NA;. "Daunorubicin liposomal." Reactions Weekly &NA;, no. 829 (2000): 7. http://dx.doi.org/10.2165/00128415-200008290-00018.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
34

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1399 (2012): 12–13. http://dx.doi.org/10.2165/00128415-201213990-00040.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
35

&NA;. "Daunorubicin/doxorubicin." Reactions Weekly &NA;, no. 373 (1991): 5. http://dx.doi.org/10.2165/00128415-199103730-00023.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
36

&NA;. "Daunorubicin/doxorubicin." Reactions Weekly &NA;, no. 423 (1992): 7. http://dx.doi.org/10.2165/00128415-199204230-00026.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
37

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1213 (2008): 16. http://dx.doi.org/10.2165/00128415-200812130-00046.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
38

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1106 (2006): 10. http://dx.doi.org/10.2165/00128415-200611060-00029.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
39

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 898 (2002): 6. http://dx.doi.org/10.2165/00128415-200208980-00015.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
40

&NA;. "Cyclophosphamide/daunorubicin." Reactions Weekly &NA;, no. 1258 (2009): 13. http://dx.doi.org/10.2165/00128415-200912580-00043.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
41

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1280 (2009): 18–19. http://dx.doi.org/10.2165/00128415-200912800-00057.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
42

&NA;. "Daunorubicin/doxorubicin." Reactions Weekly &NA;, no. 1252 (2009): 19. http://dx.doi.org/10.2165/00128415-200912520-00064.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
43

&NA;. "Daunorubicin/doxorubicin." Reactions Weekly &NA;, no. 292 (1990): 5. http://dx.doi.org/10.2165/00128415-199002920-00014.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
44

&NA;. "Daunorubicin/doxorubicin." Reactions Weekly &NA;, no. 348 (1991): 7. http://dx.doi.org/10.2165/00128415-199103480-00027.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
45

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 354 (1991): 8. http://dx.doi.org/10.2165/00128415-199103540-00026.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
46

&NA;. "Daunorubicin/mitoxantrone." Reactions Weekly &NA;, no. 1309 (2010): 18. http://dx.doi.org/10.2165/00128415-201013090-00054.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
47

&NA;. "Daunorubicin/idarubicin." Reactions Weekly &NA;, no. 946 (2003): 8–9. http://dx.doi.org/10.2165/00128415-200309460-00024.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
48

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1291 (2010): 17. http://dx.doi.org/10.2165/00128415-201012910-00050.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
49

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1294 (2010): 16. http://dx.doi.org/10.2165/00128415-201012940-00047.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
50

&NA;. "Daunorubicin/tretinoin." Reactions Weekly &NA;, no. 1301 (2010): 18. http://dx.doi.org/10.2165/00128415-201013010-00064.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!